Search
Clinician Ordering Portal
On-demand education
Gene Expression Profile Testing To Resolve Diagnostic Ambiguity In Challenging Melanocytic Lesions
May 2023
Integrating new technology into the management of non-dysplastic Barrett’s esophagus patients
Castle Biosciences hosted a case-based panel discussion at DDW 2023 highlighting how TissueCypher aids in the management of non-dysplastic Barrett’s esophagus patients.
Individualized Risk Prediction in Barrett’s Esophagus
Jul 2016
Medical Laboratory Observer
GNAQ and GNA11 mutations in uveal melanoma
Dec 2014
Melanoma Res 2014;24:525-34
Genomic research in uveal melanoma
Retina Today 2010:67-9
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death
Oct 2004
Cancer Res 2004;64:7205-9
Comprehensive Diagnostic Offering – Highly Accurate and Objective Tests for Melanocytic Lesions of Uncertain Potential
Learn About Castle’s Comprehensive Diagnostic Offering
Our suite of highly accurate tests for melanocytic lesions of uncertain potential increases diagnostic confidence and enables better clinical management plans for patients. Learn the essentials from this comprehensive introduction by Matthew Goldberg, MD, Medical Director for Castle Biosciences.